Menu Search
Equities

DiaSorin SpA

DIA:MIL

DiaSorin SpA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)105.75
  • Today's Change1.65 / 1.59%
  • Shares traded7.74k
  • 1 Year change+19.09%
  • Beta-0.1496
Data delayed at least 15 minutes, as of Nov 22 2024 09:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform2
Hold8
Sell1
Strong Sell1

Share price forecast in EUR

The 15 analysts offering 12 month price targets for DiaSorin SpA have a median target of 105.00, with a high estimate of 126.00 and a low estimate of 80.00. The median estimate represents a 0.86% increase from the last price of 104.10.
High21.0%126.00
Med0.9%105.00
Low-23.2%80.00

Dividends in EUR

Historical dividend information is not available for DiaSorin SpA.
Div growth (TTM)--
More ▼

Earnings history & estimates in EUR

On Nov 05, 2024, DiaSorin SpA reported 3rd quarter 2024 earnings of 0.84 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 3rd quarter results by 82.61%.
The next earnings announcement is expected on Mar 13, 2025.
Average growth rate+21.61%
DiaSorin SpA reported annual 2023 earnings of 2.98 per share on Mar 15, 2024.
Average growth rate+2.45%
More ▼

Revenue history & estimates in EUR

DiaSorin S.p.A. had 3rd quarter 2024 revenues of 287.00m. This bettered the 284.84m consensus of the 4 analysts covering the company. This was 0.90% below the prior year's 3rd quarter results.
Average growth rate+1.76%
DiaSorin S.p.A. had revenues for the full year 2023 of 1.15bn. This was 15.66% below the prior year's results.
Average growth rate+14.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.